Takeda Pharmaceuticals North America, Inc. And Sucampo Pharmaceuticals, Inc. Release: AMITIZA(TM) (Lubiprostone) Phase III Constipation Trial Results Demonstrate Improvements In Symptoms Of Irritable Bowel Syndrome With Constipation

LAS VEGAS, NV -- (MARKET WIRE) -- October 23, 2006 -- In recent studies, AMITIZA™ (lubiprostone) demonstrated improvements in relief of symptoms associated with irritable bowel syndrome with constipation (IBS-C), such as abdominal bloating and discomfort. Results of sub-analyses from two Phase III chronic constipation studies of AMITIZA, the first selective chloride channel activator approved by the FDA for the treatment of chronic idiopathic constipation in adults, were presented today at the 71st American College of Gastroenterology (ACG) Annual Scientific Meeting.